Humanized anti clever-1 antibodies and their use
AssigneeFaron Pharmaceuticals Oy
InventorsMikael MAKSIMOW, Markku JALKANEN, Marita VAINIO
Life of this patent
Estimating the term…
Abstract
This invention relates to an agent and a humanized antibody or single chain Fv or Fab fragment capable of binding to human CLEVER-1 recognizing an epitope of CLEVER-1, wherein the epitope is discontinuous and comprises the sequences: PFTVLVPSVSSFSSR and QEITVTFNQFTK. This invention relates also an agent capable of binding to an epitope of human CLEVER-1 for use in removing tumour or antigen induced immunosuppression. Further, the invention relates to a pharmaceutical composition comprising the agent capable of binding to human CLEVER-1 and an appropriate excipient.
Claims15
1-2. (canceled)
A method for treating cancer or chronic infection comprising administering a humanized antibody or single chain Fv or Fab fragment capable of binding to human CLEVER-1 to a patient in need of such treatment, wherein said humanized antibody or single chain Fv or Fab fragment comprises the following sequences of complementarity determining regions (CDRs)
- i) of the heavy chain
- CDR 1:
- (SEQ ID NO:
- 7)
- TSGMGIG,
- CDR 2:
- (SEQ ID NO:
- 8)
- HIWWDDDKRYNPALKS,
- and
- CDR 3:
- (SEQ ID NO:
- 9)
- HYGYDPYYAMDY;
- and
- ii) of the light chain
- CDR 1:
- (SEQ ID NO:
- 10)
- TASSSVSSSYLH,
- CDR 2:
- (SEQ ID NO:
- 11)
- RTSNLAS,
- and
- CDR 3:
- (SEQ ID NO:
- 12)
- HQYHRSPPT.
A method for treating or preventing cancer by reducing the size of a malignant tumor;
- by reducing malignant tumour growth in an individual;
- and/or by inhibiting cancer cell transmigration and metastasis formation, comprising administering a humanized antibody or single chain Fv or Fab fragment capable of binding to human CLEVER-1 to a patient in need of such treatment, wherein said humanized antibody or single chain Fv or Fab fragment comprises the following sequences of complementarity determining regions (CDRs)
- i) of the heavy chain
- CDR 1:
- (SEQ ID NO:
- 7)
- TSGMGIG,
- CDR 2:
- (SEQ ID NO:
- 8)
- HIWWDDDKRYNPALKS,
- and
- CDR 3:
- (SEQ ID NO:
- 9)
- HYGYDPYYAMDY;
- and
- ii) of the light chain
- CDR 1:
- (SEQ ID NO:
- 10)
- TASSSVSSSYLH,
- CDR 2:
- (SEQ ID NO:
- 11)
- RTSNLAS,
- and
- CDR 3:
- (SEQ ID NO:
- 12)
- HQYHRSPPT.
Dependencies are inferred from the claim text.